MedTrace Logo

RadiothErapy priMIng for CAR-T

NCT04726787 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-12-09

No results posted yet for this study

Summary

The REMIT trial will investigate radiotherapy as a preferred bridging method prior to Tisagenlecleucel infusion in patients with relapsed or refractory Diffuse Large B Cell Lymphoma

Conditions

Interventions

RADIATION

Bridging Radiotherapy

Bridging Radiotherapy will start immediately after leukapheresis and before Tisagenlecleucel treatment

Sponsors & Collaborators

Principal Investigators

  • Andrea Kuhnl · King's College Hospital NHS Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-18
Primary Completion
2023-07-05
Completion
2025-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04726787 on ClinicalTrials.gov